Fibrates, glitazones, and peroxisome proliferator-activated receptors

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 5, 2010, Pages 894-899

  Lalloyer, Fanny ^a,b,c   Staels, Bart ^a,b,c  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Atherosclerosis; Glucose homeostasis; Lipid metabolism; Nuclear receptors; Pharmacology

Indexed keywords

ANDROSTERONE; BEZAFIBRATE; CHOLESTEROL; CIPROFIBRATE; CLOBUZARIT; CLOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GEMFIBROZIL; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOBUTYRIC ACID DERIVATIVE; LEVOTHYROXINE; LIPID; LOW DENSITY LIPOPROTEIN; METHYLCLOFENAPATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHYTOHORMONE; TIBRIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ADRENAL FUNCTION; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARCINOGENICITY; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; DRUG TARGETING; DYSLIPIDEMIA; FIBRINOGEN BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEPATOMEGALY; HUMAN; HYPERCHOLESTEROLEMIA; HYPOCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; LIPID METABOLISM; LIVER CARCINOGENESIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PEROXISOME; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; REVIEW; THYROID FUNCTION;

ANIMALS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CLOFIBRIC ACID; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; DYSLIPIDEMIAS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 77951457202     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.179689     Document Type: Review

References (56)

1. Mathivat A, Cottet J. Clinical trials on the hypocholesterolemia- producing effect of 2-phenylbutyric acid [in undetermined language]. Bull Mem Soc Med Hop Paris. 1953;69:1030-1048.
2. Cottet J, Redel J, Krumm-Heller C, Tricaud ME. Hypocholesterolemic property of sodium phenylethylacetate (22 TH) in the rat [in undetermined language]. Bull Acad Natl Med. 1953;137:441-442.
3. Thorp JM, Waring WS. Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature. 1962;194:948-949.
4. Galimberti P, Defranceschi A. Intesi di alcuni derivati a-isobutirici. Gazz Chim Ital. 1947;77:431.
5. Julia M, Baillarge M, Tchernoff G. Sur quelques nouveaux derives aryloxyisobutyriques et apparentes. Bull Soc Chim Fr. 1956:776-783.
6. Thorp JM. Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate. Lancet. 1962;1: 1323-1326.
7. Oliver MF. Further observations on the effects of atromid and of ethyl chlorophenoxyisobutyrate on serum lipid levels. J Atheroscler Res. 1963; 3:427-444.
8. Hellman L, Zumoff B, Kessler G, Kara E, Rubin IL, Rosenfeld RS. Reduction of serum cholesterol and lipids by ethyl chlorophenoxyisobutyrate. J Atheroscler Res. 1963;3:454-466.
9. Hess R, Staubli W, Riess W. Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat. Nature. 1965;208: 856-858.
10. Azarnoff DL, Svoboda DJ. Microbodies in experimentally altered cells, VI: thyroxine displacement from plasma proteins and clofibrate effect. Arch Int Pharmacodyn Ther. 1969;181:386-393.
11. Svoboda D, Azarnoff D, Reddy J. Microbodies in experimentally altered cells, II: the relationship of microbody proliferation to endocrine glands. J Cell Biol. 1969;40:734-746.
12. Reddy JK, Krishnakantha TP. Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate. Science. 1975;190:787-789.
13. Matzkies F, Schulzky D, Berg G. Procetofen, a new lipid-and urine-acid-reducing substance [in German]. Fortschr Med. 1978;96:1939-1941.
14. Reddy JK, Azarnoff DL, Hignite CE. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature. 1980; 283:397-398.
15. Blumcke S, Schwartzkopff W, Lobeck H, Edmondson NA, Prentice DE, Blane GF. Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. Atherosclerosis. 1983;46:105-116.
16. Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, Wiegand HJ. Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol. 1993;31:857-907.
17. Cattley RC, DeLuca J, Elcombe C, Fenner-Crisp P, Lake BG, Marsman DS, Pastoor TA, Popp JA, Robinson DE, Schwetz B, Tugwood J, Wahli W. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol. 1998;27:47-60.
18. Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2008;5:542-553.
19. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
20. Harrold BP, Marmion VJ, Gough KR. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes. 1969;18: 285-291.
21. Kawamatsu Y, Saraie T, Imamiya E, Nishikawa K, Hamuro Y. Studies on antihyperlipidemic agents, I: synthesis and hypolipidemic activities of phenoxyphenyl alkanoic acid derivatives. Arzneimittelforschung. 1980; 30:454-459.
22. Kawamatsu Y, Asakawa H, Saraie T, Imamiya E, Nishikawa K, Hamuro Y. Studies on antihyperlipidemic agents, II: synthesis and biological activities of 2-chloro-3-arylpropionic acids. Arzneimittelforschung. 1980; 30:585-589. (Pubitemid 10145170)
23. Sohda T, Mizuno K, Tawada H, Sugiyama Y, Fujita T, Kawamatsu Y. Studies on antidiabetic agents, I: synthesis of 5-[4-(2-methyl-2-phenylpropoxy)-benzyl] thiazolidine-2,4-dione (AL-321) and related compounds. Chem Pharm Bull (Tokyo). 1982;30:3563-3573. (Pubitemid 13210096)
24. Sohda T, Mizuno K, Imamiya E, Sugiyama Y, Fujita T, Kawamatsu Y. Studies on antidiabetic agents, II: synthesis of 5-[4-(1-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives. Chem Pharm Bull (Tokyo). 1982;30: 3580-3600. (Pubitemid 13210097)
25. Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes. 1983;32:804-810.
26. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 1988;37:1549-1558.
27. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with trogli-tazone. N Engl J Med. 1998;338:916-917.
28. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes. 1994; 43:1203-1210.
29. Cantello BC, Cawthorne MA, Cottam GP, Duff PT, Haigh D, Hindley RM, Lister CA, Smith SA, Thurlby PL. [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4- thiazolidinediones as potent antihyperglycemic agents. J Med Chem. 1994;37:3977-3985.
30. Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y, Ikeda H. Studies on antidiabetic agents: synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneimittelforschung. 1990; 40:37-42.
31. Reddy JK, Goel SK, Nemali MR, Carrino JJ, Laffler TG, Reddy MK, Sperbeck SJ, Osumi T, Hashimoto T, Lalwani ND, Rao MS. Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proc Natl Acad Sci USA. 1986;83:1747-1751.
32. Staels B, van Tol A, Verhoeven G, Auwerx J. Apolipoprotein A-IV messenger ribonucleic acid abundance is regulated in a tissue-specific manner. Endocrinology. 1990;126:2153-2163.
33. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347: 645-650.
34. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 1992; 358:771-774.
35. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 1992;11:433-439.
36. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992;68:879-887.
37. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 1995;15:3012-3022.
38. Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, Vinson C, Gonzalez FJ. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res. 2004;64:3849-3854.
39. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
40. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168-1178.
41. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994;79:1147-1156.
42. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224-1234.
43. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953-12956.
44. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.
45. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
46. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WR Jr, Sternbach DD. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta): synthesis and biological activity. Bioorg Med Chem Lett. 2003;13:1517-1521.
47. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanen M, Ventre J, Wu MS, Berger GD, Mosley R, Marquis R, Santini C, Sahoo SP, Tolman RL, Smith RG, Moller DE. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999;274:6718-6725.
48. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA. 2006;103: 3444-3449.
49. Qin X, Xie X, Fan Y, Tian J, Guan Y, Wang X, Zhu Y, Wang N. Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology. 2008;48:432-441.
50. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective per-oxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA. 2001;98:5306-5311.
51. Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoul-zadegan M, Grimaldi PA. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J. 2003;17:2299-2301.
52. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol. 2004;2:e294.
53. Fievet C, Fruchart JC, Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol. 2006;6:606-614.
54. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009;374:126-135.
55. Gonzalez IC, Lamar J, Iradier F, Xu Y, Winneroski LL, York J, Yumibe N, Zink R, Montrose-Rafizadeh C, Etgen GJ, Broderick CL, Oldham BA, Mantlo N. Design and synthesis of a novel class of dual PPAR-gamma/delta agonists. Bioorg Med Chem Lett. 2007;17:1052-1055.
56. Wallace JM, Schwarz M, Coward P, Houze J, Sawyer JK, Kelley KL, Chai A, Rudel LL. Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys. J Lipid Res. 2005;46:1009-1016.